US Stock Insider Trading | Neurogene disclosed 6 insider transactions on March 17

K-LinePoet · 2026-04-02T07:26:36+00:00

On March 17, 2026, Neurogene disclosed multiple insider trading records involving executives Cobb Stuart and Cvijic Christine Mikail, including large stock sales. Neurogene is dedicated to developing innovative gene therapies for the treatment of neurological diseases.

K-LinePoet

2026-04-02 07:26:36

Abstract generation in progress

On March 17, 2026, Neurogene (NGNE) disclosed details of six insider transactions. Executive Cobb Stuart sold 3,991 shares on March 13, 2026.

【Recent Insider Transactions】

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price Per Share/US$	Total Amount/US$
March 17, 2026	Executive	Cobb Stuart	March 13, 2026	Sell	148	22.08	3,267.84
March 17, 2026	Executive	Cobb Stuart	March 13, 2026	Sell	2,658	21.34	56,700.72
March 17, 2026	Executive	Cvijic Christine Mikail	March 13, 2026	Sell	1,395	21.25	29,643.75
March 17, 2026	Executive	Cvijic Christine Mikail	March 13, 2026	Sell	2,387	20.42	48,747.14
March 17, 2026	Executive	Cvijic Christine Mikail	March 13, 2026	Sell	263	22.02	5,791.26
March 17, 2026	Executive	Cobb Stuart	March 13, 2026	Sell	3,991	20.41	81,448.36
March 3, 2026	Executive	Cvijic Christine Mikail	February 27, 2026	Sell	4,800	25.11	120,528.00
May 15, 2025	Executive	Cobb Stuart	May 14, 2025	Sell	6,797	15.15	102,911.55
March 17, 2025	Executive	Cvijic Christine Mikail	March 13, 2025	Sell	4,501	16.94	76,278.94
November 27, 2024	Shareholder with more than 10% ownership	Samsara BioCapital GP, LLC	November 26, 2024	Buy	15,200	26.73	406,656.00

【Company Profile】

Neurogene Inc. was formerly 6175813 Canada Inc. (6175813 Canada Inc.). The company was incorporated on December 26, 2003, under the Canada Business Corporations Act. Neurogene’s mission is to treat devastating neurological diseases to improve the lives of patients and families affected by these rare diseases. Neurogene is developing new approaches and treatments to address limitations of traditional gene therapy in diseases of the central nervous system. This includes selecting a delivery method to distribute as much as possible to target tissues, and designing products to maximize efficacy and purity in order to achieve optimized performance and safety. Neurogene’s new proprietary EXACT transgene regulation platform technology enables delivery at therapeutic levels while limiting transgene toxicity associated with conventional gene therapy. Neurogene is building a state-of-the-art gene therapy manufacturing facility in Houston, Texas.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.